Humacyte (NASDAQ:HUMA) CFO Sells $41,298.30 in Stock

Humacyte, Inc. (NASDAQ:HUMA) CFO Dale Sander sold 45,887 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $0.90, for a total value of $41,298.30. Following the completion of the transaction, the chief financial officer directly owned 267,213 shares in the company, valued at $240,491.70. The trade was a 14.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Humacyte Stock Performance

Shares of Humacyte stock traded up $0.09 on Wednesday, hitting $0.92. The stock had a trading volume of 4,271,551 shares, compared to its average volume of 6,504,970. Humacyte, Inc. has a twelve month low of $0.55 and a twelve month high of $2.93. The business’s 50 day moving average is $0.84 and its two-hundred day moving average is $1.05. The company has a quick ratio of 3.32, a current ratio of 3.93 and a debt-to-equity ratio of 5.46. The stock has a market cap of $203.64 million, a price-to-earnings ratio of -1.61 and a beta of 2.31.

Humacyte (NASDAQ:HUMA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%.The company had revenue of $0.50 million for the quarter, compared to the consensus estimate of $1.46 million. Analysts forecast that Humacyte, Inc. will post -0.32 EPS for the current year.

Humacyte News Roundup

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: Humacyte said its Symvess vascular graft is now under contract with the U.S. Department of Veterans Affairs Strategic Acquisition Center, which should make the product easier to access across 170 VA hospitals and may support broader adoption. Article Title
• Positive Sentiment: TD Cowen reportedly raised its price target on HUMA to $1.50 from $1.00, which can reinforce investor optimism around the stock’s potential. Article Title
• Neutral Sentiment: HC Wainwright updated its earnings estimates across several future periods, but the note still points to continued losses and only modest expected improvement over time.
• Negative Sentiment: The analyst revisions included lower EPS expectations for FY2026, FY2027 and FY2028, underscoring that Humacyte is still expected to remain unprofitable for the foreseeable future.

Institutional Investors Weigh In On Humacyte

A number of large investors have recently added to or reduced their stakes in HUMA. R Squared Ltd acquired a new stake in Humacyte during the fourth quarter worth approximately $25,000. Atom Investors LP bought a new stake in Humacyte during the fourth quarter worth $25,000. Truist Financial Corp bought a new stake in Humacyte during the third quarter worth $28,000. Prudential Financial Inc. bought a new stake in Humacyte during the second quarter worth $28,000. Finally, Financial Advisors Network Inc. bought a new stake in Humacyte during the second quarter worth $28,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on HUMA. Benchmark reduced their price target on Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, January 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of Humacyte in a research report on Friday, April 10th. BTIG Research reduced their price target on Humacyte from $3.00 to $2.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. D. Boral Capital reissued a “buy” rating and set a $25.00 price target on shares of Humacyte in a research report on Tuesday, April 28th. Finally, Wall Street Zen raised Humacyte from a “strong sell” rating to a “sell” rating in a research report on Saturday. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.57.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.